@article{3109853,
    title = "Comment on “rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial”",
    author = "Vassilakopoulos, T.P. and Apostolidis, J. and Angelopoulou, M.K.",
    journal = "Haematologica-the hematology journal",
    year = "2015",
    volume = "100",
    number = "11",
    pages = "e480-e481",
    publisher = "Ferrata Storti Foundation",
    doi = "10.3324/haematol.2015.133223",
    keywords = "rituximab;  antineoplastic agent;  rituximab, B cell lymphoma;  bone marrow;  clinical trial (topic);  drug efficacy;  event free survival;  female;  gender;  human;  large cell lymphoma;  Letter;  male;  overall survival;  unspecified side effect;  Lymphoma, Follicular;  Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols;  Female;  Humans;  Lymphoma, Follicular;  Lymphoma, Large B-Cell, Diffuse;  Male;  Rituximab"
}